M. Atzori

发表

A novel and atypical NF-KB pro-inflammatory program regulated by a CamKII-proteasome axis is involved in the early activation of Muller glia by high glucose

P. Cascio, P. Lacal, G. Graziani, 2021, Cell & bioscience.

Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug

P. Cascio, F. Polticelli, M. Coletta, 2022, Biomolecules.

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib

M. Barbaccia, L. Tentori, P. Lacal, 2019, Journal of cellular and molecular medicine.

A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.

C. Leonetti, A. Mai, L. Tentori, 2015, Biochemical pharmacology.

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells

R. Pallini, R. Bjerkvig, L. Tentori, 2017, Journal of Experimental & Clinical Cancer Research.

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding

L. Tentori, P. Lacal, G. Graziani, 2016, Oncotarget.

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug

P. Ascierto, E. Bonmassar, G. Palmieri, 2012, Journal of Translational Medicine.

Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma

P. Lacal, M. Atzori, Claudia Ceci, 2020, Cancers.

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells

R. Pallini, R. Bjerkvig, L. Tentori, 2017, Journal of experimental & clinical cancer research : CR.

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models

P. Lacal, M. Atzori, Claudia Ceci, 2020, International journal of molecular sciences.

Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells.

L. Tentori, P. Lacal, M. Atzori, 2018, Oncology reports.

Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.

L. Tentori, P. Lacal, M. Atzori, 2020, Pharmacological research.

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug

P. Ascierto, E. Bonmassar, G. Palmieri, 2012, Journal of Translational Medicine.

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor

P. Lacal, M. Atzori, M. Scimeca, 2022, Cancers.

The Anti–Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo

L. Tentori, P. Lacal, M. Atzori, 2018, The Journal of Pharmacology and Experimental Therapeutics.